N. Martin

发表

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Alan Ashworth, Ian Hickson, Nuala McCabe, 2005, Nature.

Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

O. Sansom, T. Hay, A. Clarke, 2005, Cancer research.

2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK).

I. Hardcastle, R. Griffin, B. Golding, 2003, Bioorganic & medicinal chemistry letters.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

N. Curtin, I. Hardcastle, R. Griffin, 2007, Journal of medicinal chemistry.

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

A. Tutt, A. Nussenzweig, S. Boulton, 2021, Nature Communications.

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

A. Lau, M. O’Connor, T. Hay, 2009, Cancer research.

DNA repair inhibition and cancer therapy.

N. Martin, Niall M.B Martin, Niall M. B. Martin, 2001, Journal of Photochemistry and Photobiology. B: Biology.

5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).

M. D. Lloyd, P. Wood, M. Threadgill, 2011, Journal of medicinal chemistry.

Progress in the Function and Regulation of ADP-Ribosylation

R. Plummer, Zhao-Qi Wang, M. Boothby, 2011, Science Signaling.

Chemical Therapeutics Preclinical Evaluation of a Novel ATM Inhibitor , KU 59403 , In Vitro and In Vivo in p 53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013 .

The PARP inhibitor AZD 2461 is differentiated from olaparib for both PARP 3 activity and drug resistance

M. Pajic, A. Lau, M. O’Connor, 2017 .

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

M. Pajic, A. Lau, M. O’Connor, 2016, Cancer research.

Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.

Krystyna J. Dillon, N. Martin, G. Smith, 2006, Bioorganic & medicinal chemistry letters.

Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase.

N. Martin, G. Smith, K. Menear, 2008, Bioorganic & medicinal chemistry letters.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

A. Lau, M. O’Connor, C. Knights, 2008, Journal of medicinal chemistry.

Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.

Krystyna J. Dillon, N. Martin, G. Smith, 2005, Bioorganic & medicinal chemistry letters.

Regulation of the activity and expression of ERK8 by DNA damage

P. Cohen, Iva Klevernic, N. Martin, 2009, FEBS letters.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

A. Ashworth, A. Tutt, C. Lord, 2005, Cancer biology & therapy.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

A. Ashworth, A. Tutt, S. Jackson, 2005, Cold Spring Harbor symposia on quantitative biology.

A FlashPlate Assay for the Identification of PARP-1 Inhibitors

Krystyna J. Dillon, N. Martin, G. Smith, 2003, Journal of biomolecular screening.

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

N. Curtin, S. Jackson, P. Reaper, 2004, Cancer Research.

Targeted cancer therapies based on the inhibition of DNA strand break repair

M. O’Connor, N. Martin, G. Smith, 2007, Oncogene.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

P. Borst, A. Lau, M. O’Connor, 2008, Proceedings of the National Academy of Sciences.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Shridar Ganesan, Jos Jonkers, Piet Borst, 2013, Cancer discovery.

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

N. Curtin, R. Griffin, Yan Zhao, 2011, Molecular Cancer Therapeutics.

Deubiquitylating enzymes and drug discovery: emerging opportunities

Stephen P. Jackson, X. Jacq, S. Jackson, 2017, Nature Reviews Drug Discovery.

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

A. Lau, M. O’Connor, J. Jonkers, 2008, Clinical Cancer Research.

Selective Inhibition of BRCA 2-Deficient MammaryTumor Cell Growth byAZD 2281 and Cisplatin

A. Lau, M. O’Connor, J. Jonkers, 2008 .

Deubiquitylating Enzymes and DNA Damage Response Pathways

X. Jacq, S. Jackson, N. Martin, 2013, Cell Biochemistry and Biophysics.

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013, Molecular Cancer Therapeutics.

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

P. Workman, L. Kèlland, F. Raynaud, 2005, British Journal of Cancer.

Synthesis of 4-alkyl-, 4-aryl- and 4-arylamino-5-aminoisoquinolin-1-ones and identification of a new PARP-2 selective inhibitor.

M. D. Lloyd, M. Threadgill, M. Mahon, 2011, Organic & biomolecular chemistry.

319 POSTER Pharmacodynamics and anti-tumour activity of KU-0063794, a potent and specific inhibitor of mTOR kinase

C. Chresta, B. Davies, Ian D. Hickson, 2008 .

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

N. Curtin, R. Griffin, Yan Zhao, 2012, Molecular Cancer Therapeutics.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

S. Ganesan, J. Doroshow, P. Borst, 2013, Cancer discovery.

2,6‐Disubstituted Pyran‐4‐one and Thiopyran‐4‐one Inhibitors of DNA‐Dependent Protein Kinase (DNA‐PK).

I. Hardcastle, R. Griffin, B. Golding, 2003 .